Substance + claimed effects

L-glutamine is a non-essential, conditionally essential amino acid: the most abundant free amino acid in human plasma (~600–700 µmol/L) and the dominant species in the skeletal-muscle intracellular free-amino-acid pool (~60% of the non-taurine pool, on the order of 20 mmol/L) Cruzat et al. 2018. Endogenous synthesis (~10–25 g/day, primarily in skeletal muscle via glutamine synthetase) covers normal needs; supplementation only matters when demand exceeds supply, which happens in catabolic stress (trauma, sepsis, burns, very prolonged exercise) and when a metabolically demanding tissue (enterocytes, lymphocytes) loses its preferred fuel Cruzat et al. 2018. Sold as a free-form powder (5–10 g per dose, $20–40 for a multi-month supply) for "gut healing" and "recovery". The entry covers the four named consequences in the brief — intestinal barrier integrity, immune function, post-exercise recovery, glucose handling — plus an honest treatment of where the supplement consistently underperforms versus where it has earned its niche (post-infectious IBS, sickle-cell pain crises, endurance-athlete gut leak, severe burns/parenteral nutrition).

Evidence by addressing question

mechanism

Enterocyte fuel. Small-bowel epithelial cells (enterocytes) and immune cells (lymphocytes, macrophages, neutrophils) use glutamine at rates comparable to or greater than glucose Cruzat et al. 2018. The gut extracts a substantial fraction of dietary and arterial glutamine on first pass — splanchnic uptake is so high that oral glutamine raises gut tissue concentrations far more than it raises peripheral plasma. This is why oral dosing targets gut more efficiently than it targets muscle.

Tight junctions. In Caco-2 monolayers, porcine jejunal epithelium, and rodent stress models, glutamine deprivation collapses expression of the tight-junction proteins claudin-1, claudin-4, occludin, and ZO-1/2; restoring glutamine restores them, with proposed signalling through CaMK kinase 2 → AMPK and through HSP70/mTOR Wang et al. 2015. The translational claim — that this protects the barrier in humans under physiologic stress — is supported in narrow conditions (heat-exercise, post-infectious IBS) but does not generalise.

Immune cell metabolism. Glutamine is essential substrate for lymphocyte proliferation, cytokine synthesis, macrophage phagocytic activity, and neutrophil bacterial killing Cruzat et al. 2018. Plasma glutamine falls after prolonged exercise; Newsholme and Castell hypothesised that this fall causes the post-exercise "open window" of infection susceptibility Castell et al. 1996. The hypothesis turned out to overstate causality (in-vitro glutamine concentrations needed to limit lymphocyte function are far below the post-exercise nadir) but the link between supplementation and reduced URTI rates has survived in narrower form.

GLP-1 secretion. Oral glutamine triggers L-cell release of GLP-1 (and glucagon, and insulin) more strongly than equivalent doses of other amino acids in healthy, obese, and type-2 diabetic subjects — the substrate-induced incretin effect Greenfield et al. 2009. This is the mechanism behind glutamine's modest postprandial glucose-lowering effect, not an insulin-sensitising effect at the muscle.

evidence

Gut permeability — pooled. A 2024 systematic review and meta-analysis of 10 RCTs (n=352) found no overall effect of glutamine on intestinal permeability across all populations and doses pooled. The signal appeared only in subgroup analysis: doses above ~30 g/day for less than two weeks reduced permeability; lower-dose chronic protocols did not Singleton et al. 2024. This is the most important honest framing of the gut-barrier literature: there is a real effect, but it requires a much higher dose, in a stressed barrier, on a much shorter timeline, than the "5 g of glutamine in my morning shake forever" pattern most consumers run.

Post-infectious IBS-D. The cleanest positive trial: 106 adults with post-infectious diarrhoea-predominant IBS and documented increased intestinal permeability (Rome III IBS-D, lactulose/mannitol elevated) randomised to 5 g three-times-daily L-glutamine (15 g/day) vs maltodextrin placebo for 8 weeks. The glutamine arm achieved the primary endpoint (≥50-point IBS-SS reduction) at 79.6% vs 5.8% for placebo, with normalisation of lactulose/mannitol ratio Zhou et al. 2019. Effect size is unusually large for an IBS trial; the population was tightly selected (post-infectious, permeability-elevated subset), so generalisability beyond that phenotype is unproven.

Exercise-induced gut leak. Zuhl et al. 2014 randomised 8 runners to glutamine (0.9 g/kg fat-free mass for 7 days) or placebo before a 60-min treadmill run; lactulose/rhamnose permeability ratio was elevated by exercise on placebo and held at baseline on glutamine, with parallel upregulation of intestinal claudin-1 in biopsied tissue Zuhl et al. 2014. Pugh et al. 2017 ran a dose-response in 10 athletes (0, 0.25, 0.5, 0.9 g/kg) running in the heat — a clear dose-dependent attenuation of permeability, with effects beginning at 0.25 g/kg (~17 g for a 70-kg athlete) taken 2 h before exercise Pugh et al. 2017. Both are small mechanistic studies; clinical-symptom endpoints (GI distress, performance) less consistently replicate.

Upper-respiratory infection in endurance athletes. Castell et al. 1996 — the still-cited foundational result — pooled marathon and ultra-marathon runners (n=151) drinking 5 g glutamine vs placebo immediately and 2 h after the race. Self-reported URTI in the week following the race: 19% on glutamine vs 51% on placebo Castell et al. 1996. Replication has been mixed; a 2019 meta-analysis of glutamine in athletes found no convincing effect on performance or body composition, with the immune-function signal limited to post-endurance specifically Ramezani Ahmadi et al. 2019. The original effect probably reflects a real but narrow window: very prolonged exercise + immediate post-event dosing.

Critical care — the harm signal. The REDOXS trial (n=1223 ICU patients with multi-organ failure on mechanical ventilation) randomised early high-dose glutamine (0.35 g/kg/day IV + 30 g/day enteral, started within 24 h) vs placebo in a 2×2 factorial with antioxidants. 28-day mortality was no different, but in-hospital mortality (32.4% vs 27.2%) and 6-month mortality were higher on glutamine — a clear harm signal, concentrated in patients with renal failure at enrollment Heyland et al. 2013. RE-ENERGIZE (n=1200, severe burns ≥20% body surface area, 0.5 g/kg/day enteral glutamine for ≥7 days) found no benefit on time to discharge alive, 6-month mortality, length of stay, or bacteraemia — and post hoc no harm Heyland et al. 2022. ESPEN's 2023 ICU guideline reflects the resulting caution: parenteral glutamine only in patients on exclusive parenteral nutrition, enteral glutamine 0.3–0.5 g/kg/day specifically in major burns for 10–15 days; not routine Singer et al. 2023.

Post-exercise muscle recovery. Legault et al. 2015: 8 men, eccentric knee-extension protocol, 0.3 g/kg L-glutamine four times daily vs placebo for 72 h. Strength recovery was modestly accelerated at 48 h and 72 h on glutamine; soreness ratings lower in men. Small, single-centre Legault et al. 2015. The Ramezani-Ahmadi meta-analysis confirms the pattern: a small attenuation of soreness with no measurable effect on muscle-damage biomarkers (CK, LDH), no effect on strength or hypertrophy in chronic protocols Ramezani Ahmadi et al. 2019. As a muscle-building or strength-recovery supplement, glutamine is essentially inert.

Glucose handling. Greenfield et al. 2009 gave 30 g oral glutamine to lean, obese, and T2D subjects; glutamine raised GLP-1, insulin, and glucagon dose-dependently in all groups Greenfield et al. 2009. Samocha-Bonet et al. 2011 then showed that adding 30 g glutamine to a standard meal in T2D patients reduced 3-h postprandial glucose AUC by ~10% and augmented active GLP-1 — a real but modest effect, well below what GLP-1 agonist drugs achieve Samocha-Bonet et al. 2011. Longer trials (4–6 weeks) showed weaker/inconsistent fasting-glucose and HbA_1c effects; the postprandial signal is the robust one.

Sickle-cell disease. Tangential to the brief but relevant context: the Phase 3 Niihara trial of pharmaceutical-grade L-glutamine (0.3 g/kg twice daily, oral) in 230 sickle-cell patients reduced median sickle-cell pain crises from 3 to 3 (intervention) vs 4 (placebo), hospitalisations from 3 to 2, and hospital days Niihara et al. 2018. FDA-approved as Endari in July 2017 FDA 2017. The mechanism is hypothesised to be NAD redox support in sickled erythrocytes. This is a prescription use; not what the catalogue's typical reader is doing with the powder, but it is the cleanest evidence of a real systemic effect at a defined dose.

protocol

The trial-supported regimens, by indication:

• Post-infectious IBS-D with documented hyperpermeability: 5 g three times daily (15 g/day) for 8 weeks Zhou et al. 2019.
• Endurance athletes for exercise-induced gut leak: 0.25–0.9 g/kg taken 1–2 h pre-event (~17–60 g for a 70-kg athlete); 7 days of pre-loading at 0.9 g/kg/fat-free-mass also shown effective Pugh et al. 2017 Zuhl et al. 2014.
• Endurance-athlete URTI prophylaxis: 5 g immediately post-race and again at 2 h Castell et al. 1996.
• Severe burns ≥20% BSA in hospital: 0.3–0.5 g/kg/day enteral for 10–15 days Singer et al. 2023. Inpatient only.
• Sickle-cell crisis prophylaxis: 0.3 g/kg twice daily as the prescription product Endari Niihara et al. 2018.

The common consumer protocol — 5 g once daily, indefinitely, with no underlying stressor or barrier injury — has no trial backing. It is at best the lower bound of doses that have done anything in any trial.

contraindications

The safety profile is favourable at consumer doses: Garlick's safety assessment found no adverse effects at up to 0.65 g/kg/day acute in healthy adults Garlick 2001; chronic use at 5–30 g/day has not produced consistent laboratory abnormalities Cruzat et al. 2018. The exceptions are not academic:

• Critical illness with multi-organ failure or renal failure. Early high-dose IV+enteral glutamine increased mortality in REDOXS Heyland et al. 2013. Not a consumer issue, but the supplement should be stopped on ICU admission.
• Liver failure / cirrhosis. Glutamine is metabolised to glutamate and ammonia; a compromised urea cycle plus high glutamine load can worsen hepatic encephalopathy.
• Reye-syndrome-like states / inborn errors of urea cycle. Same ammonia-handling concern.
• Bipolar disorder, seizure disorders. Theoretical (glutamine → glutamate, an excitatory neurotransmitter); not well-quantified, but reported in case literature.

misconceptions

"Leaky gut → take glutamine" is the supplement-influencer pitch and is mostly wrong as framed. The pooled meta-analysis is negative at consumer doses; the positive trials require a documented permeability defect (post-infectious IBS, exercise-induced) and either much higher acute doses or specific timing Singleton et al. 2024. Daily 5 g for a healthy person with normal digestion has no demonstrated effect on barrier function.

"More glutamine = more muscle." The bodybuilding-magazine claim. Healthy adults already synthesize 10–25 g/day endogenously; exogenous glutamine does not raise muscle protein synthesis or improve strength/hypertrophy in any meta-analysed RCT Ramezani Ahmadi et al. 2019 Gleeson 2008. The soreness signal is modest; the strength/mass signal is null.

"Plasma glutamine drops after exercise, so we need to top it up." The "glutamine hypothesis" of post-exercise immunodepression has not aged well — the in-vitro concentrations at which lymphocyte function is impaired sit far below the post-exercise nadir, and most randomised trials of glutamine for immune endpoints in trained athletes are null. Castell's URTI signal remains real for the prolonged-exercise post-event window specifically, not for chronic supplementation in general Cruzat et al. 2018.

"It's an amino acid, so it's just safer protein." True at supplement doses; false at ICU doses. REDOXS is a real harm signal in a specific population, not a hypothetical Heyland et al. 2013.

failure-modes

• Wrong population. Healthy adult with no gut symptoms and no endurance training takes 5 g/day and notices nothing. The substrate is already abundant; adding more does nothing.
• Wrong dose for the gut claim. The barrier-effect doses are 15 g/day (IBS-D), 17–60 g acute (endurance), 30+ g/day (the pooled meta-analysis subgroup). The default 5 g/day is below the floor for the barrier indication.
• Wrong timing for the URTI claim. Immediate post-event matters; chronic daily background does not appear to.
• Treating glutamine as a substitute for actually addressing the cause. The post-infectious IBS-D trial worked because the population had a defined barrier lesion; chronic SIBO, food intolerance, or undiagnosed celiac is not fixed by glutamine.

practicalities

Free-form L-glutamine powder, ~$15–30 for 500 g (90 servings at 5 g, 30 days at 15 g). Unflavoured, slightly sweet, water-soluble. Stable at room temperature. Pharmacopeial purity is generally good (NSF-certified products exist for athletes). The prescription form (Endari) is dramatically more expensive but identical molecule.

Mild GI side effects (bloating, loose stool) reported above ~10 g/dose; splitting larger daily totals across doses helps. Should be taken with water, not with high-carbohydrate meals that compete for splanchnic absorption.

stakes

For the supplement-aisle reader chasing "gut health" — modest stakes either way. The default 5 g/day is unlikely to harm and unlikely to help. The deeper cost is opportunity: time and money spent on a low-yield supplement instead of fibre, fermented foods, sleep, or a workup for actual GI symptoms (celiac, SIBO, IBD, food intolerance) — interventions with real effect sizes.

For the endurance athlete with race-day GI distress — a real, well-documented problem cluster (cramping, urgency, post-race URTI) that this supplement can partially address. Skipping it is a missed cheap intervention.

payoff

Realistic payoffs by population:

• Post-infectious IBS-D with leaky barrier: ~80% chance of a meaningful symptom reduction over 8 weeks (Zhou trial primary endpoint) Zhou et al. 2019.
• Endurance athlete with race-day GI distress: smaller, less consistent reduction in symptoms; clearer reduction in laboratory permeability markers; modest reduction in post-race URTI.
• T2D postprandial control: ~10% reduction in postprandial glucose AUC when 30 g taken with the meal Samocha-Bonet et al. 2011. Real but small in absolute terms.
• Healthy adult chasing "gut health" or muscle: no detectable payoff.

audience

The candidate audiences are narrower than the marketing implies: post-infectious IBS-D (sub-population of IBS-D, themselves ~5% of adults); endurance athletes during heavy training; severe-burn inpatients (hospital-only); sickle-cell patients (prescription); type-2 diabetics seeking adjunct postprandial control. The mass-market audience implied by supplement shelves — "anyone with bloating," "anyone training" — is the wrong audience.

The credibility range

Optimist case

Glutamine is the primary fuel for the cells whose dysfunction we now think drives many of modern medicine's chronic conditions — enterocytes (gut barrier → systemic inflammation), immune cells (susceptibility to infection), L-cells (incretin response → glucose control). Mechanism is rigorously characterised in vitro and in vivo; the relevant tissues extract it on first pass, so oral dosing reaches them. The cleanest human trial — Zhou's post-infectious IBS-D study — shows a dramatic effect size (~80% responder rate vs 6%) in a well-defined phenotype. The exercise-permeability literature is consistent across multiple labs. The FDA approved L-glutamine for sickle cell on the basis of a phase-3 trial. The harm signals are confined to one specific ICU population on dramatically higher doses; consumer dosing has a clean safety record over decades.

Skeptic case

The 2024 meta-analysis is null at the population level; only a subgroup of high-dose short-duration trials moves the needle. Castell's 1996 URTI result has not been cleanly replicated in three decades. The 2019 athletic-performance meta-analysis is fully null for the consumer outcomes (strength, hypertrophy, body composition, chronic immune endpoints). The original "glutamine hypothesis" of post-exercise immunodepression is mechanistically incoherent at the relevant plasma concentrations. The supplement industry promotes a "leaky-gut → glutamine" pipeline that is unsupported in healthy adults. The IBS-D trial is one centre, one 8-week endpoint, in a heavily selected subgroup, and has not been independently replicated. The ICU literature shows real harm in the wrong population, which forces caution about the broader "more must be better" framing. And glutamine is cheap precisely because it is endogenously synthesized in 10–25 g/day amounts already — exogenous dosing is meaningful only when this synthesis is overrun.

Author's call

Glutamine is a real, narrow intervention with three or four legitimate use cases (post-infectious IBS-D with documented barrier dysfunction; endurance-athlete gut leak and post-race immune dip; severe burns under medical supervision; sickle-cell crisis prophylaxis as a prescription drug) and a much larger zone of consumer mythology around generic "gut healing" and "muscle recovery". The article's job is to draw that line cleanly: name the populations where the trial dose works, name the dose, name the duration, and otherwise call the daily-5-g habit what it is — low-cost, low-yield, generally harmless. Evidence rating sits at 3 — multiple solid mechanism studies and one strong RCT (Zhou) for the gut-barrier use, plus a Phase-3 trial in sickle cell, but the broader consumer claims do not have RCT support and the meta-analyses are mostly null. Controversy ~2 — the field does not really disagree about the underlying science; the disagreement is in marketing, not in mechanism.

Stakeholder + incentive map

• Supplement industry. Glutamine is a high-margin bulk amino acid (cheap to produce, easy to market as "recovery" or "gut health"). The "leaky gut" narrative is a profitable consumer pitch even where the evidence does not support it.
• Sports-nutrition publications. Long-running affinity for the Castell hypothesis; the muscle-recovery claim survives in popular print well after RCTs nulled it.
• Critical-care community. Largely retreated from routine glutamine after REDOXS; ESPEN's 2023 guideline reflects the chastened view.
• Gastroenterology. Cautiously interested for post-infectious IBS-D after Zhou 2019; few clinicians use it as first-line yet.
• Emmaus Medical / sickle-cell community. Endari is FDA-approved; usage is real but not universal because uptake of L-glutamine has been less than hydroxyurea and newer agents.

Population variability

• Documented hyperpermeability matters. Zhou's positive trial required elevated lactulose/mannitol at baseline; subgroups with normal permeability did not respond — the substrate ceiling matters.
• Training load matters. Effects on gut permeability are clearest under heavy endurance load (≥60 min, often in heat). Casual exercisers show no permeability defect to correct.
• Catabolic stress matters. Endogenous synthesis covers needs in healthy adults; trauma, sepsis, burns, prolonged starvation, and intense exercise can outrun synthesis. The supplement is "essential" only in those windows.
• Renal function matters. Renal failure was the harm-modifier in REDOXS; glutamine clearance is reduced and ammonia load rises.
• Diabetes/T2D. The GLP-1 response and postprandial glucose effect are larger in T2D than in lean controls — likely because GLP-1 reserve is higher in the unstimulated state in T2D.

Knowledge gaps

• No independent replication of the Zhou 2019 IBS-D trial. Until it lands, the 5-g-TID-for-8-weeks protocol rests on a single study.
• No long-term safety data for chronic high-dose (15–30 g/day) consumer use beyond ~2 months.
• The exercise-permeability → infection-rate chain is plausible but the direct evidence linking glutamine's permeability effect to clinical outcomes (sick days, performance) is thin.
• The interaction between glutamine and modern incretin/GLP-1 agonist drugs in T2D is unstudied; the GLP-1 axis is now saturated by drug effect in many of these patients.
• No head-to-head against bovine colostrum or zinc-carnosine for exercise-induced gut leak.

Narrowing versus the brief. The topic brief named four consequences (gut barrier, immune function, muscle recovery, glucose handling) and the article covers all four — but three of them land on a negative or sharply qualified verdict at consumer doses, which is the honest read of the evidence. The dek and tagline frame this as a "decide" entry rather than a "do" because the population-level pitches the supplement industry runs do not hold up; the entry's job is to name the narrow populations where the trial dose works and warn off the rest.

Scoring choices worth flagging.

• health_short_term at 2 is a deliberately weighted average. For the post-infection IBS-D subgroup in Zhou 2019 the effect would warrant a 4; for the rest of the catalogue's reader base it is a 0. The 2 reflects the honest expectation across "the typical reader of this entry," not a flat average across all uses.
• longevity scored 0 despite the sickle-cell and burn data, because those are prescription/hospital uses and not what the catalogue reader is doing with the powder.
• energy, focus, sleep, mood all 0 — none of these have RCT support and the dossier is silent on them; resisted the urge to score 1 on energy "because amino acids".
• evidence at 3 reflects the split: one strong RCT (Zhou 2019) plus solid mechanism and a Phase 3 sickle-cell trial, against a null pooled meta-analysis and a null athletic-performance meta. Could argue for 2; landed at 3 because Zhou is genuinely high-quality and the FDA-approval anchor is real.
• contraindications token: only kidney-disease from the closed vocabulary fit cleanly. The liver-failure and seizure cautions are noted in the article body but don't have a matching token.

Excluded on purpose.

• Detailed sickle-cell protocol — that is a prescription drug use (Endari), not what consumers are buying glutamine powder for. Cited as anchor for "real systemic effects exist at defined doses" and left there.
• Burn-unit detail — same reasoning; included as evidence anchor, not as a consumer protocol.
• The full critical-care literature beyond Heyland 2013 (REDOXS) — RE-ENERGIZE (Heyland 2022) is in the research dossier but not the article, since the burn story is in-hospital only and adding a second critical-care trial to a consumer-facing article muddied the read.
• HMB, BCAAs, and other amino-acid recovery alternatives — adjacent entries, flagged as future links rather than handled here.

Future link candidates. A dedicated post-infectious IBS entry (currently absent) would carry the Zhou 2019 protocol with more clinical detail and is the right home for that material long-term; this entry's protocol callout is the supplement-side projection of it. A runner's gut / exercise-induced gut permeability entry would consolidate Pugh/Zuhl and let this entry just cross-link. A creatine entry, an FODMAP-elimination entry, a celiac screening entry — all named in out-of-scope, all candidates for cross-links once they exist.

Hard decision during the write. Whether to lead the dek with relief/debunking voice or with the narrow positive case. Picked the relief framing because the dominant reader is the supplement-aisle shopper, not the IBS patient — the article serves both, but the hook earns its read by surprising the larger audience. Dream narrative was optional at this score (~10); written anyway to anchor the tagline's "marketed for everyone, works for almost no one" lever.

Rating difficulty. applicability was the hardest call. The legitimate aggregate audience (post-infection IBS-D + endurance athletes + T2D adjunct + sickle cell + burns) is wider than any one of them, but each remains a small slice. Landed at 2 ("meaningful slice, ~5–15%") rather than 3 because no single one of these populations reaches a quarter of adults.